WO2005003157A3 - Interferon variants with improved properties - Google Patents

Interferon variants with improved properties Download PDF

Info

Publication number
WO2005003157A3
WO2005003157A3 PCT/US2004/009824 US2004009824W WO2005003157A3 WO 2005003157 A3 WO2005003157 A3 WO 2005003157A3 US 2004009824 W US2004009824 W US 2004009824W WO 2005003157 A3 WO2005003157 A3 WO 2005003157A3
Authority
WO
WIPO (PCT)
Prior art keywords
improved properties
interferon variants
interferon
variants
properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/009824
Other languages
French (fr)
Other versions
WO2005003157A2 (en
Inventor
Anna Marie Aguinaldo
Amelia Joy Beyna
Ho Sung Cho
John Rudolph Desjarlais
Shannon Alicia Marshall
Umesh Muchhal
Michael Francis Aquin Villegas
Eugene Zhukovsky
Michael Stephen Quesenberry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/676,705 external-priority patent/US20040137581A1/en
Application filed by Xencor Inc filed Critical Xencor Inc
Priority to CA002528964A priority Critical patent/CA2528964A1/en
Priority to EP04785771A priority patent/EP1636256A2/en
Priority to AU2004253847A priority patent/AU2004253847A1/en
Publication of WO2005003157A2 publication Critical patent/WO2005003157A2/en
Publication of WO2005003157A3 publication Critical patent/WO2005003157A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to interferon variants with improved properties and methods for their use.
PCT/US2004/009824 2003-06-10 2004-03-30 Interferon variants with improved properties Ceased WO2005003157A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002528964A CA2528964A1 (en) 2003-06-10 2004-03-30 Interferon variants with improved properties
EP04785771A EP1636256A2 (en) 2003-06-10 2004-03-30 Interferon variants with improved properties
AU2004253847A AU2004253847A1 (en) 2003-06-10 2004-03-30 Interferon variants with improved properties

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US47724603P 2003-06-10 2003-06-10
US60/477,246 2003-06-10
US48972503P 2003-07-24 2003-07-24
US60/489,725 2003-07-24
US10/676,705 US20040137581A1 (en) 2002-10-01 2003-09-30 Interferon variants with improved properties
PCT/US2003/030802 WO2004031352A2 (en) 2002-10-01 2003-09-30 Interferon variants with improved properties
USPCT/US03/30802 2003-09-30
US10/676,705 2003-09-30

Publications (2)

Publication Number Publication Date
WO2005003157A2 WO2005003157A2 (en) 2005-01-13
WO2005003157A3 true WO2005003157A3 (en) 2005-02-24

Family

ID=34198925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009824 Ceased WO2005003157A2 (en) 2003-06-10 2004-03-30 Interferon variants with improved properties

Country Status (2)

Country Link
EP (1) EP1636256A2 (en)
WO (1) WO2005003157A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632492B2 (en) 2006-05-02 2009-12-15 Allozyne, Inc. Modified human interferon-β polypeptides
US7998469B2 (en) 2002-09-09 2011-08-16 Hanall Biopharma Co., Ltd. Protease resistant interferon beta mutants

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111745A2 (en) * 2005-04-20 2006-10-26 Viragen Incorporated Composition and method for treating viral infection
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
FR2907454B1 (en) * 2006-10-18 2009-01-23 Biomethodes Sa IMPROVED VARIANTS OF INTERFERON BETA HUMAIN
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
CN114835793A (en) * 2015-11-16 2022-08-02 Ubi蛋白公司 Method for extending protein half-life
RU2650755C1 (en) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Method for cleaning the medicament of prolonged action on the basis of the recombinant analogue of alpha-17 interferon for viral hepatitis c treatment
CN112043685A (en) * 2020-09-18 2020-12-08 深圳科兴药业有限公司 Recombinant human interferon alpha 1b mutant inhalation solution and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048018A1 (en) * 1997-04-23 1998-10-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Recombinant human beta interferon with enhanced solubility
WO2002074783A2 (en) * 2001-03-15 2002-09-26 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048018A1 (en) * 1997-04-23 1998-10-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Recombinant human beta interferon with enhanced solubility
WO2002074783A2 (en) * 2001-03-15 2002-09-26 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARSHALL SHANNON A ET AL: "Rational design and engineering of therapeutic proteins.", DRUG DISCOVERY TODAY, vol. 8, no. 5, 1 March 2003 (2003-03-01), pages 212 - 221, XP002295833, ISSN: 1359-6446 *
RUNKEL LAURA ET AL: "Differences in activity between alpha and beta type I interferons explored by mutational analysis", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 14, 3 April 1998 (1998-04-03), pages 8003 - 8008, XP002160242, ISSN: 0021-9258 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998469B2 (en) 2002-09-09 2011-08-16 Hanall Biopharma Co., Ltd. Protease resistant interferon beta mutants
US8052964B2 (en) 2002-09-09 2011-11-08 Hanall Biopharma Co., Ltd. Interferon-β mutants with increased anti-proliferative activity
US8057787B2 (en) 2002-09-09 2011-11-15 Hanall Biopharma Co., Ltd. Protease resistant modified interferon-beta polypeptides
US7632492B2 (en) 2006-05-02 2009-12-15 Allozyne, Inc. Modified human interferon-β polypeptides

Also Published As

Publication number Publication date
WO2005003157A2 (en) 2005-01-13
EP1636256A2 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
WO2005097825A3 (en) Bmp-7 variants with improved properties
AP2280A (en) Compositions and methods for increasing telomeraseactivity.
EP1664746A4 (en) Antioxodant sensor, methods and compositions
IL211133A0 (en) Anti-il-6 antibodies, compositions, methods and uses
PL1651042T3 (en) Herbicidal composition having the herbicidal effect enhanced, and method for enhancing the herbicidal effect
WO2006073968A3 (en) Derivatized 3,4-alkylenedioxythiophene monomers, methods of making them, and use thereof
WO2004031352A3 (en) Interferon variants with improved properties
AP2005003420A0 (en) Acidic composition and its uses.
IL173521A0 (en) Substituted 2 - carbonylamino - 6 piperidinaminopyidines and substituted 1 - carbonylamino - 3 - piperidinaminobenzenes as 5 - th1f agonists
WO2005110009A8 (en) COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d
EP1711527A4 (en) Hla-dr-specific antibodies, compositions and methods
WO2005003157A3 (en) Interferon variants with improved properties
EP1607316A4 (en) Combine
IL172184A0 (en) Interferon gamma - like protein
GB2399268B (en) Throttle
IL177759A0 (en) Cospeptin, cosmedin and their uses
AU2003232176A8 (en) Protein c variants with altered properties
AU2003247216A1 (en) Novel sphinogmyelinase, the antibody against it, the antisense and the preparation method thereof
AU2003207994A1 (en) Engine
HK1098462A (en) 2-propene-1-ones as hsp 70 inducers
GB0327838D0 (en) Foresight
AU2003286989A1 (en) The personal autoflusher
AU2003901418A0 (en) Sirna
AU2003906800A0 (en) Composition and Methods
AU2003901731A0 (en) Clip

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2528964

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004253847

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004785771

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004253847

Country of ref document: AU

Date of ref document: 20040330

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004253847

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004785771

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004785771

Country of ref document: EP